Recently, I've been looking into the biotech sector, especially companies related to gene therapy, which is quite interesting. This field has indeed gained popularity over the past two years. After the FDA approved several gene therapy products at the end of 2023, major pharmaceutical companies have started to compete for a share, whether through licensing or acquisitions.

Gene therapy actually changes the traditional logic of drug development. Instead of simply treating symptoms, it fundamentally modifies or replaces a patient's genes to cure diseases. The potential is huge, but the risks are also significant—high costs, uncertain side effects, and questions about market acceptance. However, in this volatile biotech landscape, the demand for innovative therapies remains strong.

The three gene therapy companies I've been paying attention to are quite worth watching. First is Sarepta. Their product Elevidys was approved for Duchenne Muscular Dystrophy (DMD), and last June, they received an expanded label approval to treat all DMD patients over 4 years old. The performance of this product already looks like a blockbuster. Sarepta's stock rose 31.5% last year, and they are also advancing other gene therapies for neuromuscular diseases, with plans to submit an FDA application for a limb-girdle muscular dystrophy (LGMD) candidate mid-term.

CRISPR Therapeutics is another key player. Their CRISPR/Cas9-based therapy Casgevy was approved for sickle cell disease and transfusion-dependent beta-thalassemia, developed and commercialized in partnership with Vertex. They are now developing next-generation CAR-T therapies, with two products in Phase 1/2 trials. The company's stock continues to attract attention, with analyst target prices suggesting an increase of nearly 85%.

Voyager Therapeutics also has a solid pipeline, mainly focusing on gene therapies for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Their lead product, VY7523, has completed a single-dose escalation study, with safety data expected to be announced in the first half of this year. Plus, they have collaborations with AstraZeneca and Novartis, which is a plus.

From an investment perspective, the stock opportunities in this wave of gene therapy companies are still worth paying attention to. Although the field is uncertain, the demand for innovative therapies is clear, and these companies' pipelines are progressing. If you're interested in biotech, these three could be added to your watchlist.